JP7025432B2 - Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 - Google Patents
Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 Download PDFInfo
- Publication number
- JP7025432B2 JP7025432B2 JP2019534192A JP2019534192A JP7025432B2 JP 7025432 B2 JP7025432 B2 JP 7025432B2 JP 2019534192 A JP2019534192 A JP 2019534192A JP 2019534192 A JP2019534192 A JP 2019534192A JP 7025432 B2 JP7025432 B2 JP 7025432B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyran
- compound
- methyl
- isoindoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CC(C1)=CCc2c1cccc2 Chemical compound *CC(C1)=CCc2c1cccc2 0.000 description 17
- UHEVNPHRPRHQGH-UHFFFAOYSA-N BrCC1CCNCC1 Chemical compound BrCC1CCNCC1 UHEVNPHRPRHQGH-UHFFFAOYSA-N 0.000 description 1
- GOCGWQXAPGQXGA-UHFFFAOYSA-N C#CCNC(c1ccc(CCl)cc1)=O Chemical compound C#CCNC(c1ccc(CCl)cc1)=O GOCGWQXAPGQXGA-UHFFFAOYSA-N 0.000 description 1
- HTAJKFUPEFNKQD-UHFFFAOYSA-N C/C=S(\c1ccc(COC2=COC(CN3Cc4ccccc4C3)=CC2=O)cc1)/N(C)C(C)=O Chemical compound C/C=S(\c1ccc(COC2=COC(CN3Cc4ccccc4C3)=CC2=O)cc1)/N(C)C(C)=O HTAJKFUPEFNKQD-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- WLNQPBMEFYCTOG-UHFFFAOYSA-N C1S[N]1(C1)Cc2c1cccc2 Chemical compound C1S[N]1(C1)Cc2c1cccc2 WLNQPBMEFYCTOG-UHFFFAOYSA-N 0.000 description 1
- JTOCXIOOHUCNJB-UHFFFAOYSA-N C=[Br]c1c[n](-c2ccc(CBr)cc2)nc1 Chemical compound C=[Br]c1c[n](-c2ccc(CBr)cc2)nc1 JTOCXIOOHUCNJB-UHFFFAOYSA-N 0.000 description 1
- KCZCJKYDDRQUKC-UHFFFAOYSA-N CC(C)C(N1CCC(COC2=COC(CN3Cc4ccccc4C3)=CC2=O)CC1)O Chemical compound CC(C)C(N1CCC(COC2=COC(CN3Cc4ccccc4C3)=CC2=O)CC1)O KCZCJKYDDRQUKC-UHFFFAOYSA-N 0.000 description 1
- FJATZRCLBFVHER-UHFFFAOYSA-N CC(CC1)=CC1S Chemical compound CC(CC1)=CC1S FJATZRCLBFVHER-UHFFFAOYSA-N 0.000 description 1
- QBLSEYFSECQFHK-UHFFFAOYSA-N CCCCCCNC(c1ccc(CCl)cc1)=O Chemical compound CCCCCCNC(c1ccc(CCl)cc1)=O QBLSEYFSECQFHK-UHFFFAOYSA-N 0.000 description 1
- VZIKCNLKNWDJSA-UHFFFAOYSA-N CCCCNC(c1ccc(CCl)cc1)=O Chemical compound CCCCNC(c1ccc(CCl)cc1)=O VZIKCNLKNWDJSA-UHFFFAOYSA-N 0.000 description 1
- KZBDMXFIDCWCOU-UHFFFAOYSA-N CCN(CC)C(c1ccc(CCl)cc1)=O Chemical compound CCN(CC)C(c1ccc(CCl)cc1)=O KZBDMXFIDCWCOU-UHFFFAOYSA-N 0.000 description 1
- IACYGTPEKZKTBS-UHFFFAOYSA-N CCN=S(C)(c1ccc(CCl)cc1)=O Chemical compound CCN=S(C)(c1ccc(CCl)cc1)=O IACYGTPEKZKTBS-UHFFFAOYSA-N 0.000 description 1
- MXQKRJBRKTTYMU-UHFFFAOYSA-N CN(C)C(C(CC1)CCC1C(OC)=O)=O Chemical compound CN(C)C(C(CC1)CCC1C(OC)=O)=O MXQKRJBRKTTYMU-UHFFFAOYSA-N 0.000 description 1
- CMXBYINWLGVYBA-BUSXIPJBSA-N CN(C1C[C@@H](COC2=COC(CN3Cc4ccccc4C3)=CC2=O)CC1)S=O Chemical compound CN(C1C[C@@H](COC2=COC(CN3Cc4ccccc4C3)=CC2=O)CC1)S=O CMXBYINWLGVYBA-BUSXIPJBSA-N 0.000 description 1
- AZWJQOPYJHSPRA-UHFFFAOYSA-N CN(Cc1c2ccc(CO)c1)C2=O Chemical compound CN(Cc1c2ccc(CO)c1)C2=O AZWJQOPYJHSPRA-UHFFFAOYSA-N 0.000 description 1
- DTEXILGOBOJCQG-UHFFFAOYSA-N CNC(C1CCC(CO)CC1)=O Chemical compound CNC(C1CCC(CO)CC1)=O DTEXILGOBOJCQG-UHFFFAOYSA-N 0.000 description 1
- SLHBCCWDHOSOHN-UHFFFAOYSA-N CNS(C1=CCC(CBr)C=C1)(=O)=O Chemical compound CNS(C1=CCC(CBr)C=C1)(=O)=O SLHBCCWDHOSOHN-UHFFFAOYSA-N 0.000 description 1
- ZQJNPHCQABYENK-UHFFFAOYSA-N COC(C(CC1)CCC1C(O)=O)=O Chemical compound COC(C(CC1)CCC1C(O)=O)=O ZQJNPHCQABYENK-UHFFFAOYSA-N 0.000 description 1
- LOIAOYYTUMKKCK-UHFFFAOYSA-N CS(N1CCC(COC2=COC(CCl)=CC2=O)CC1)(=O)=O Chemical compound CS(N1CCC(COC2=COC(CCl)=CC2=O)CC1)(=O)=O LOIAOYYTUMKKCK-UHFFFAOYSA-N 0.000 description 1
- DFBVGWUMJXPNCG-UHFFFAOYSA-N CS(N1CCC(COC2=COC(CN(Cc3ccc4F)Cc3c4F)=CC2=O)CC1)(=O)=O Chemical compound CS(N1CCC(COC2=COC(CN(Cc3ccc4F)Cc3c4F)=CC2=O)CC1)(=O)=O DFBVGWUMJXPNCG-UHFFFAOYSA-N 0.000 description 1
- OXJSFIXGFSSETB-UHFFFAOYSA-N CS(c1ccc(CCl)cc1)(=N)=O Chemical compound CS(c1ccc(CCl)cc1)(=N)=O OXJSFIXGFSSETB-UHFFFAOYSA-N 0.000 description 1
- FEIVTHCUCOBCNA-UHFFFAOYSA-N CSc1ccc(CN(CC(OC=C2O)=CC2=O)C2)c2c1 Chemical compound CSc1ccc(CN(CC(OC=C2O)=CC2=O)C2)c2c1 FEIVTHCUCOBCNA-UHFFFAOYSA-N 0.000 description 1
- QHNOFICCGDHAGY-UHFFFAOYSA-N Cc(cc1)ccc1S(N=S(C)(c1ccc(CCl)cc1)=O)(=O)=O Chemical compound Cc(cc1)ccc1S(N=S(C)(c1ccc(CCl)cc1)=O)(=O)=O QHNOFICCGDHAGY-UHFFFAOYSA-N 0.000 description 1
- WNWYEAGEJSMPJW-UHFFFAOYSA-N Cc(cc1)ccc1S(OCC(CC1)CCN1C(C1CC1)=O)(=O)=O Chemical compound Cc(cc1)ccc1S(OCC(CC1)CCN1C(C1CC1)=O)(=O)=O WNWYEAGEJSMPJW-UHFFFAOYSA-N 0.000 description 1
- GEIUZTVZSHDJOO-UHFFFAOYSA-N Cc(cc1)ccc1S(OCC(CC1)CCN1C(CS(C)(=O)=O)=O)(=O)=O Chemical compound Cc(cc1)ccc1S(OCC(CC1)CCN1C(CS(C)(=O)=O)=O)(=O)=O GEIUZTVZSHDJOO-UHFFFAOYSA-N 0.000 description 1
- KFNQAYDGVQSDFT-UHFFFAOYSA-N ClCc(cc1)ccc1-[n]1nncc1 Chemical compound ClCc(cc1)ccc1-[n]1nncc1 KFNQAYDGVQSDFT-UHFFFAOYSA-N 0.000 description 1
- FOMQOEHZFJEHAP-UHFFFAOYSA-N Fc1ccc(CNC2)c2c1F Chemical compound Fc1ccc(CNC2)c2c1F FOMQOEHZFJEHAP-UHFFFAOYSA-N 0.000 description 1
- XCVZLKJBFRDHMR-UHFFFAOYSA-N NC(c1cc(F)c(CBr)cc1)=O Chemical compound NC(c1cc(F)c(CBr)cc1)=O XCVZLKJBFRDHMR-UHFFFAOYSA-N 0.000 description 1
- WGXYNHYXVDRNCU-MBIQTGHCSA-N NC1C[C@@H](COC2=COC(CN(C3)Cc4c3cccc4)=CC2=O)CC1 Chemical compound NC1C[C@@H](COC2=COC(CN(C3)Cc4c3cccc4)=CC2=O)CC1 WGXYNHYXVDRNCU-MBIQTGHCSA-N 0.000 description 1
- BMOCIRHCNKTQGC-UHFFFAOYSA-N O=C(C(F)(F)F)N1CCC(COC2=COC(CN3Cc4ccccc4C3)CC2=O)CC1 Chemical compound O=C(C(F)(F)F)N1CCC(COC2=COC(CN3Cc4ccccc4C3)CC2=O)CC1 BMOCIRHCNKTQGC-UHFFFAOYSA-N 0.000 description 1
- ARMMDQIVPBFNLH-UHFFFAOYSA-N OC(c1c2cc(C(F)(F)F)cc1)N(CC(OC=C1O)=CC1=O)C2=O Chemical compound OC(c1c2cc(C(F)(F)F)cc1)N(CC(OC=C1O)=CC1=O)C2=O ARMMDQIVPBFNLH-UHFFFAOYSA-N 0.000 description 1
- GYISJBANZFFZCW-UHFFFAOYSA-N OC(c1cc(C(F)(F)F)ccc11)N(CC(OC=C2O)=CC2=O)C1=O Chemical compound OC(c1cc(C(F)(F)F)ccc11)N(CC(OC=C2O)=CC2=O)C1=O GYISJBANZFFZCW-UHFFFAOYSA-N 0.000 description 1
- LFMGJNUSGPWNMW-UHFFFAOYSA-N OC1(COC1)c1ccc(CCl)cc1 Chemical compound OC1(COC1)c1ccc(CCl)cc1 LFMGJNUSGPWNMW-UHFFFAOYSA-N 0.000 description 1
- MZSBKRMQLAGNEK-UHFFFAOYSA-N OC1=COC(CN(C2)Cc3c2ccc(OC(F)(F)F)c3)=CC1=O Chemical compound OC1=COC(CN(C2)Cc3c2ccc(OC(F)(F)F)c3)=CC1=O MZSBKRMQLAGNEK-UHFFFAOYSA-N 0.000 description 1
- RZYWTDLWXFNYNS-UHFFFAOYSA-N OC1=COC(CN(C2)Cc3c2cccc3)=CC1=O Chemical compound OC1=COC(CN(C2)Cc3c2cccc3)=CC1=O RZYWTDLWXFNYNS-UHFFFAOYSA-N 0.000 description 1
- MHSHKYQGEAQPMA-UHFFFAOYSA-N OC1=COC(CN(CC2)Cc3c2cccc3)=CC1=O Chemical compound OC1=COC(CN(CC2)Cc3c2cccc3)=CC1=O MHSHKYQGEAQPMA-UHFFFAOYSA-N 0.000 description 1
- JILNWDWVBOWNCJ-UHFFFAOYSA-N OC1=COC(CN(Cc2c3ccc(C(F)(F)F)c2)C3=O)=CC1=O Chemical compound OC1=COC(CN(Cc2c3ccc(C(F)(F)F)c2)C3=O)=CC1=O JILNWDWVBOWNCJ-UHFFFAOYSA-N 0.000 description 1
- JMAIKCGJGUXCKD-UHFFFAOYSA-N OC1=COC(CN(Cc2ccc(C(F)(F)I)cc22)C2=O)=CC1=O Chemical compound OC1=COC(CN(Cc2ccc(C(F)(F)I)cc22)C2=O)=CC1=O JMAIKCGJGUXCKD-UHFFFAOYSA-N 0.000 description 1
- JPHFBBBHVANQIH-UHFFFAOYSA-N OC1=COC(CN(Cc2ccc3)Cc2c3I)=CC1=O Chemical compound OC1=COC(CN(Cc2ccc3)Cc2c3I)=CC1=O JPHFBBBHVANQIH-UHFFFAOYSA-N 0.000 description 1
- UGKPDUFAKNBONO-UHFFFAOYSA-N OCC1CCC(CN(CCC2)S2(=O)=O)CC1 Chemical compound OCC1CCC(CN(CCC2)S2(=O)=O)CC1 UGKPDUFAKNBONO-UHFFFAOYSA-N 0.000 description 1
- ZCTWNRBXLSRJCL-UHFFFAOYSA-N OCCCNC(c1ccc(CCl)cc1)=O Chemical compound OCCCNC(c1ccc(CCl)cc1)=O ZCTWNRBXLSRJCL-UHFFFAOYSA-N 0.000 description 1
- OPLCYGTZYZLOKI-UHFFFAOYSA-N ON(C1)Cc2c1cccc2 Chemical compound ON(C1)Cc2c1cccc2 OPLCYGTZYZLOKI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022019891A JP7286825B2 (ja) | 2016-12-22 | 2022-02-10 | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| FI20166024 | 2016-12-22 | ||
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019891A Division JP7286825B2 (ja) | 2016-12-22 | 2022-02-10 | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502229A JP2020502229A (ja) | 2020-01-23 |
| JP2020502229A5 JP2020502229A5 (enExample) | 2021-09-30 |
| JP7025432B2 true JP7025432B2 (ja) | 2022-02-24 |
Family
ID=61005837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534192A Active JP7025432B2 (ja) | 2016-12-22 | 2017-12-21 | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
| JP2022019891A Active JP7286825B2 (ja) | 2016-12-22 | 2022-02-10 | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019891A Active JP7286825B2 (ja) | 2016-12-22 | 2022-02-10 | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (enExample) |
| EP (2) | EP3558981B1 (enExample) |
| JP (2) | JP7025432B2 (enExample) |
| KR (3) | KR102826021B1 (enExample) |
| CN (2) | CN116162084B (enExample) |
| AR (1) | AR110412A1 (enExample) |
| AU (2) | AU2017380282B2 (enExample) |
| CA (1) | CA3047370A1 (enExample) |
| CL (1) | CL2019001728A1 (enExample) |
| CO (1) | CO2019007321A2 (enExample) |
| CY (1) | CY1124461T1 (enExample) |
| DK (1) | DK3558981T3 (enExample) |
| EA (1) | EA039309B1 (enExample) |
| ES (1) | ES2880151T3 (enExample) |
| HR (1) | HRP20211255T1 (enExample) |
| HU (1) | HUE056540T2 (enExample) |
| IL (2) | IL267484B (enExample) |
| LT (1) | LT3558981T (enExample) |
| MA (2) | MA55983A (enExample) |
| MX (1) | MX388538B (enExample) |
| PE (1) | PE20191137A1 (enExample) |
| PH (1) | PH12019550111A1 (enExample) |
| PL (1) | PL3558981T3 (enExample) |
| PT (1) | PT3558981T (enExample) |
| RS (1) | RS62198B1 (enExample) |
| SI (1) | SI3558981T1 (enExample) |
| TN (1) | TN2019000189A1 (enExample) |
| TW (2) | TWI762544B (enExample) |
| UA (1) | UA124640C2 (enExample) |
| WO (1) | WO2018115591A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022078068A (ja) * | 2016-12-22 | 2022-05-24 | オリオン コーポレーション | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115551831A (zh) * | 2020-05-14 | 2022-12-30 | 奥赖恩公司 | Cyp11a1抑制剂 |
| CN116724034B (zh) * | 2020-12-01 | 2026-06-05 | 奥赖恩公司 | 作为用于治疗前列腺癌的cyp11a1抑制剂的2,3-二氢-4h-苯并[b][1,4]噁嗪-4-基)(5-(苯基)-吡啶-3-基)甲酮衍生物和类似化合物 |
| CN117279893A (zh) | 2021-03-01 | 2023-12-22 | 奥仁公司 | 用于制备cyp11a1抑制剂及其中间体的方法 |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| CN117242070A (zh) * | 2021-03-01 | 2023-12-15 | 奥仁公司 | 4h-吡喃-4-酮结构化cyp11a1抑制剂的固体形式 |
| AU2022297768A1 (en) | 2021-06-23 | 2024-01-18 | Orion Corporation | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
| EP4408426A1 (en) * | 2021-09-28 | 2024-08-07 | Orion Corporation | Cyp11a1 inhibitor for use in the treatment of prostate cancer |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| EP4430027A1 (en) | 2021-11-10 | 2024-09-18 | Orion Corporation | Cyp11a1 inhibitors |
| KR20240130101A (ko) | 2022-01-20 | 2024-08-28 | 오리온 코포레이션 | Cyp11a1 억제제의 약제 조성물 |
| CN118307519A (zh) * | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| TW202440557A (zh) | 2023-03-29 | 2024-10-16 | 大陸商西藏海思科製藥有限公司 | Cyp11a1抑制劑及其用途 |
| JP2026514915A (ja) | 2023-04-21 | 2026-05-13 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｃｙｐ１１ａ１阻害剤及びその用途 |
| KR20260040160A (ko) * | 2023-05-11 | 2026-03-24 | 셴젠 이오노바 라이프 사이언스 시오., 엘티디. | Cyp11a1 억제제로서의 신규 화합물 및 그 용도 |
| EP4746854A1 (en) | 2023-07-19 | 2026-05-27 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| CN121889383A (zh) * | 2023-09-08 | 2026-04-17 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
| TW202613102A (zh) * | 2024-05-27 | 2026-04-01 | 大陸商遼寧海思科製藥有限公司 | Cyp11a1抑制劑的鹽及其晶型、其製備方法和應用 |
| WO2026021515A1 (zh) * | 2024-07-25 | 2026-01-29 | 海思科制药(眉山)有限公司 | 一种cyp11a1抑制剂的制备方法 |
| WO2026040949A1 (zh) * | 2024-08-19 | 2026-02-26 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的药物组合物及其制备方法和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076445A2 (en) | 2003-02-28 | 2004-09-10 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014202827A1 (en) | 2013-06-11 | 2014-12-24 | Orion Corporation | Novel cyp17 inhibitors/antiandrogens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| AR110412A1 (es) | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076445A2 (en) | 2003-02-28 | 2004-09-10 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014202827A1 (en) | 2013-06-11 | 2014-12-24 | Orion Corporation | Novel cyp17 inhibitors/antiandrogens |
Non-Patent Citations (23)
| Title |
|---|
| CAS REGISTRY NO. 898418-19-4，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898418-21-8，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898418-30-9，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898418-32-1，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898420-98-9，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898439-66-2，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898440-17-0，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898441-66-2，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898456-78-5，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 898465-63-9，DATABASE REGISTRY, [online]，2006年08月03日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903268-49-5，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903268-71-3，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903268-87-1，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903269-05-6，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903269-22-7，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903313-11-1，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903316-69-8，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903319-10-8，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903320-59-2，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903338-05-6，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903356-81-0，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 903356-98-9，DATABASE REGISTRY, [online]，2006年08月22日，[2021年 4月30日検索], Retrieved from: STN |
| CAS REGISTRY NO. 906162-99-0，DATABASE REGISTRY, [online]，2006年09月10日，[2021年 4月30日検索], Retrieved from: STN |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022078068A (ja) * | 2016-12-22 | 2022-05-24 | オリオン コーポレーション | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
| JP7286825B2 (ja) | 2016-12-22 | 2023-06-05 | オリオン コーポレーション | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7286825B2 (ja) | Ｃｙｐ１１ａ１（チトクロムｐ４５０モノオキシゲナーゼ１１ａ１）阻害剤としてのピラン誘導体 | |
| ES2903423T3 (es) | Inhibidores de la desmetilasa 1 específica de lisina | |
| KR20230010723A (ko) | Cyp11a1 억제제 | |
| TW201315727A (zh) | 尿嘧啶衍生物及其醫藥用途 | |
| WO2018021977A1 (en) | Glycine metabolism modulators and uses thereof | |
| JP2018533551A (ja) | 治療用化合物及びその使用方法 | |
| HK40093308A (en) | Pyran derivatives as cyp11a1 inhibitors | |
| EP3212638B1 (en) | New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors | |
| BR122024021737A2 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos | |
| BR112019012906B1 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos | |
| HK40016600B (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| HK40016600A (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200610 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210518 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20210817 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7025432 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |